On July 16, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement agreement between Amgen, Inc. (“Amgen”) and Accord BioPharma, Inc. (“Accord”)...more
7/24/2025
/ Amgen ,
Biosimilars ,
Case Consolidation ,
Consent Agreements ,
Intellectual Property Litigation ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Pharmaceutical Patents ,
Prescription Drugs ,
Settlement Agreements
On May 15, 2025, a jury returned a verdict finding Amgen Inc. (“Amgen”) liable for antitrust violations and awarding Regeneron Pharmaceuticals, Inc. (“Regeneron”) over $400 million in damages....more
5/20/2025
/ Amgen ,
Antitrust Litigation ,
Antitrust Violations ,
Damages ,
Jury Verdicts ,
Monopolization ,
Pharmaceutical Industry ,
Regeneron ,
Sherman Act ,
The Clayton Act ,
Unfair Competition
On February 28, Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents assigned to Bristol-Myers Squibb Co. (“BMS”). The claims of all three patents are...more
On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a settlement agreement between Amgen and Celltrion resolving the BPCIA litigation regarding...more